Dermatology Innovation Leadership Think Tank

May 19, 2021

Dermatology Innovation Leadership Think Tank

Event time and date

11:00 am - 12:00 pm

Event Details

CAR-T Cells as a Therapy for γδ T-cell Cancers


Join us at the Dermatology Innovation Leadership Think Tank meeting featuring Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.

The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.

Webinar Takeaways:

Who Should Attend?

About the Presenters:

Penn Medicine’s Aimee Payne, MD, PhD, continues to re-define this field. Dr. Payne is Professor of Dermatology and Director of the Penn Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. She is also co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio (NASDAQ:CABA), focused on targeted cellular immunotherapies of B cell-mediated diseases. Her group invented a precision cellular immunotherapy for autoimmunity known as DSG3-CAART, which is being evaluated in a first-in-human clinical trial that launched in 2020.

Christoph Ellebrecht, MD, rising Clinical Instructor of Dermatology and co-inventor of DSG3-CAART, is now expanding CAR-T technology to create one of the few programs targeting gamma-delta T cell cancers, a rapidly lethal group of cancers notoriously refractory to current chemotherapeutic approaches. Targeting the gamma-delta T cell receptor with CAR T cells offers a potentially curative therapy for this devastating group of cancers with high unmet need for effective treatments.